Sterile Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-01-2025
- Paid Up Capital ₹ 0.10 M
as on 05-01-2025
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Revenue %
(FY 2022)
- Net Worth -846.04%
(FY 2022)
- Total Assets -24.63%
(FY 2022)
About Sterile Pharma
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mayureshwar Rasam and Yogini Devrukhakar serve as directors at the Company.
- CIN/LLPIN
U24304MH2020PTC344933
- Company No.
344933
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Aug 2020
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Sterile Pharma Private Limited offer?
Sterile Pharma Private Limited offers a wide range of products and services, including Crates, Trays and Pallets, Metal Pallets, Milling & Grinding Tools, Grinding Mill, Cleanroom Equipment & Supplies, Pass Box, Chemical Plants & Machinery, Ointment Manufacturing Plant, Metal Furniture Suppliers, Metal Table.
Who are the key members and board of directors at Sterile Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayureshwar Rasam  | Director | 31-Aug-2020 | Current |
| Yogini Devrukhakar | Director | 31-Aug-2020 | Current |
Financial Performance of Sterile Pharma.
Sterile Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 846.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sterile Pharma?
Unlock access to Sterile Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sterile Pharma?
Sterile Pharma has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sterile Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sterile Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
